The FY17 Defense Appropriations Act provides $4 million (M) to the Department of Defense Alcohol and Substance Abuse Disorders Research Program Research Program (ASADRP). The ASADRP is seeking applications to explore integrated approaches to address alcohol and substance use disorder (ASUD) especially related to traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD) through multidisciplinary, team-based research efforts that translate basic knowledge into enhanced clinical pharmacological treatments protocols. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).
FY17 ASADRP Program Announcement and General Application Instruction for the following award mechanisms are posted on the Grants.gov website.
Consortium Award – Letter of Intent Due September 13
Independent intramural (DoD) and extramural investigators at all academic levels (or equivalents) are eligible to submit applications
The ASADRP is seeking applications to explore integrated approaches to address alcohol and substance use disorder (ASUD) especially related to traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD) through multidisciplinary, team-based research efforts that translate basic knowledge into enhanced clinical pharmacological treatments protocols.
· The program’s approach is to organize multidisciplinary, team-based translational research efforts to:
· Identify promising compounds;
· Conduct proof-of-principle basic research to determine which compounds are most appropriate for human research trials;
· Conduct human proof-of-concept trials with promising compounds. This approach should accelerate the translation of contemporary basic science knowledge into enhanced clinical pharmacological treatment protocols for ASUD, including a regulatory strategy for U.S. Food and Drug Administration (FDA) compliance.
· The CDMRP expects to allocate FY17-19 funding, if appropriated, to fund approximately one ASADRP Consortium Award. The maximum period of performance is 5 years. The ASADRP Consortium will be funded initially with allocations from the FY17 ASADRP Congressional appropriation ($3.532M). The maximum allowable total costs (direct and indirect) for the entire period of performance are $10.596M (base year plus 2 option years). Two additional options, to be included in the application, may be funded from allocations from the FY18 & FY19 Congressional appropriation (up to $3.532M each year) subject to Government Steering Committee (GSC) review, approval of the Grants Officer, and receipt of future congressional appropriations.
A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.
Applications must be submitted through the federal government’s single-entry portal, Grants.gov. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.For more information about the ASADRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).
Point of Contact:
CDMRP Help Desk
301-682-5507
help@eBrap.org
Promoting Partnerships To Improve Veterans’ Health